These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 17919619

  • 1. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.
    Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH.
    J Heart Lung Transplant; 2007 Oct; 26(10):998-1003. PubMed ID: 17919619
    [Abstract] [Full Text] [Related]

  • 2. Recovery of renal function in heart transplantation patients after conversion from a calcineurin inhibitor-based therapy to sirolimus.
    Ayub-Ferreira SM, Avila MS, Feitosa FS, Souza GE, Mangini S, Marcondes-Braga FG, Issa VS, Bacal F, Chizzola PR, Cruz FD, Bocchi EA.
    Transplant Proc; 2010 Mar; 42(2):542-4. PubMed ID: 20304188
    [Abstract] [Full Text] [Related]

  • 3. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 4. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR, Boumitri M, Budev M, Alao B, Poggio ED.
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [Abstract] [Full Text] [Related]

  • 5. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.
    J Heart Lung Transplant; 2005 Dec; 24(12):2129-36. PubMed ID: 16364861
    [Abstract] [Full Text] [Related]

  • 6. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA.
    Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
    [Abstract] [Full Text] [Related]

  • 7. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [Abstract] [Full Text] [Related]

  • 8. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.
    Transplantation; 2007 Aug 27; 84(4):467-74. PubMed ID: 17713429
    [Abstract] [Full Text] [Related]

  • 9. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation.
    Hunt J, Lerman M, Magee MJ, Dewey TM, Herbert M, Mack MJ.
    J Heart Lung Transplant; 2005 Nov 27; 24(11):1863-7. PubMed ID: 16297793
    [Abstract] [Full Text] [Related]

  • 10. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
    Potter BJ, Giannetti N, Edwardes MD, Cecere R, Cantarovich M.
    Clin Transplant; 2007 Nov 27; 21(3):305-8. PubMed ID: 17488377
    [Abstract] [Full Text] [Related]

  • 11. Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus.
    Bäckman L, Reisaeter AV, Wramner L, Ericzon BG, Salmela K, Brattström C.
    Clin Transplant; 2006 Nov 27; 20(3):336-9. PubMed ID: 16824151
    [Abstract] [Full Text] [Related]

  • 12. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ.
    Clin Transplant; 2004 Nov 27; 18 Suppl 12():61-6. PubMed ID: 15217410
    [Abstract] [Full Text] [Related]

  • 13. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 14. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 27; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 15. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A, Zúñiga-Varga J, Correa-Rotter R, Alberú J.
    Transplant Proc; 2009 Dec 27; 41(10):4138-46. PubMed ID: 20005355
    [Abstract] [Full Text] [Related]

  • 16. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients.
    Kaplinsky E, González-Costello J, Manito N, Roca J, Barbosa MJ, Nebot M, Salazar-Mendiguchia J, Berdejo J, Mañas P, Miralles A, Cequier A.
    Transplant Proc; 2012 Nov 27; 44(9):2564-6. PubMed ID: 23146455
    [Abstract] [Full Text] [Related]

  • 17. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G.
    Liver Transpl; 2008 May 27; 14(5):651-9. PubMed ID: 18433069
    [Abstract] [Full Text] [Related]

  • 18. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Bergh CH.
    Transplantation; 2010 Apr 15; 89(7):864-72. PubMed ID: 20061999
    [Abstract] [Full Text] [Related]

  • 19. Sirolimus experience in heart transplantation.
    Aranda-Dios A, Lage E, Sobrino JM, Mogollón MV, Guisado A, Cabezón S, Hinojosa R, Hernández A, Ordóñez A.
    Transplant Proc; 2006 Oct 15; 38(8):2547-9. PubMed ID: 17097997
    [Abstract] [Full Text] [Related]

  • 20. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC, Mueller T, Arbeiter K, Boehm M, Regele H, Balzar E, Aufricht C.
    Pediatr Transplant; 2006 Jun 15; 10(4):474-8. PubMed ID: 16712606
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.